NASDAQ:GALT - Galectin Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.58 +0.11 (+2.46 %) (As of 01/16/2019 09:01 AM ET)Previous Close$4.47Today's Range$4.47 - $4.6552-Week Range$3.10 - $9.49Volume198,694 shsAverage Volume283,346 shsMarket Capitalization$183.88 millionP/E Ratio-9.35Dividend YieldN/ABeta2.99 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia. Receive GALT News and Ratings via Email Sign-up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GALT Previous Symbol CUSIPN/A Webwww.galectintherapeutics.com Phone678-620-3186Debt Debt-to-Equity RatioN/A Current Ratio6.42 Quick Ratio6.42Price-To-Earnings Trailing P/E Ratio-9.35 Forward P/E Ratio-12.05 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.22) per share Price / Book-20.82Profitability EPS (Most Recent Fiscal Year)($0.49) Net Income$-16,230,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-171.23%Miscellaneous Employees7 Outstanding Shares41,140,000Market Cap$183.88 million OptionableOptionable Galectin Therapeutics (NASDAQ:GALT) Frequently Asked Questions What is Galectin Therapeutics' stock symbol? Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT." How were Galectin Therapeutics' earnings last quarter? Galectin Therapeutics Inc. (NASDAQ:GALT) announced its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.02. View Galectin Therapeutics' Earnings History. When is Galectin Therapeutics' next earnings date? Galectin Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, April 4th 2019. View Earnings Estimates for Galectin Therapeutics. What price target have analysts set for GALT? 1 brokers have issued twelve-month price targets for Galectin Therapeutics' shares. Their forecasts range from $12.00 to $12.00. On average, they expect Galectin Therapeutics' stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 162.0% from the stock's current price. View Analyst Price Targets for Galectin Therapeutics. What is the consensus analysts' recommendation for Galectin Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galectin Therapeutics. Has Galectin Therapeutics been receiving favorable news coverage? News stories about GALT stock have trended very positive on Wednesday, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Galectin Therapeutics earned a daily sentiment score of 3.7 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. Who are some of Galectin Therapeutics' key competitors? Some companies that are related to Galectin Therapeutics include AC Immune (ACIU), G1 Therapeutics (GTHX), Revance Therapeutics (RVNC), Radius Health (RDUS), Intra-Cellular Therapies (ITCI), Urogen Pharma (URGN), Rocket Pharmaceuticals (RCKT), Dynavax Technologies (DVAX), CannTrust (CNTTF), Dicerna Pharmaceuticals (DRNA), Vectura Group (VEGPF), ANI Pharmaceuticals (ANIP), Aurinia Pharmaceuticals (AUPH), Ra Pharmaceuticals (RARX) and Kura Oncology (KURA). Who are Galectin Therapeutics' key executives? Galectin Therapeutics' management team includes the folowing people: Dr. Harold H. Shlevin, Pres & CEO (Age 69)Mr. Jack W. Callicutt, Chief Financial Officer (Age 52)Robert Tritt, Gen. CounselDr. Eliezer Zomer, Exec. VP of Manufacturing & Product Devel. (Age 72)Mr. Steven Schubert, VP of Fin. How do I buy shares of Galectin Therapeutics? Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Galectin Therapeutics' stock price today? One share of GALT stock can currently be purchased for approximately $4.58. How big of a company is Galectin Therapeutics? Galectin Therapeutics has a market capitalization of $183.88 million. The company earns $-16,230,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Galectin Therapeutics employs 7 workers across the globe. What is Galectin Therapeutics' official website? The official website for Galectin Therapeutics is http://www.galectintherapeutics.com. How can I contact Galectin Therapeutics? Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at 678-620-3186 or via email at [email protected] MarketBeat Community Rating for Galectin Therapeutics (NASDAQ GALT)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 246 (Vote Outperform)Underperform Votes: 204 (Vote Underperform)Total Votes: 450MarketBeat's community ratings are surveys of what our community members think about Galectin Therapeutics and other stocks. Vote "Outperform" if you believe GALT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GALT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/16/2019 by MarketBeat.com StaffFeatured Article: What are no-load funds?